CD141 Monoclonal Antibody (JAA17), PE-Cyanine7, eBioscience™, Invitrogen™

Description

• This JAA17 monoclonal antibody recognizes human CD141 also known as thrombomodulin, fetomodulin, or BDCA-3
• CD141 is a type I membrane receptor that binds and allosterically activates thrombin
• The resulting complex cleaves protein C and the Thrombin Activatable Fibrinolysis Inhibitor (TAFI), initiating an important anticoagulant and anti-fibrinolytic pathway
• Soluble thrombomodulin is constitutively present in the serum at a very low level and can be upregulated during inflammation
• The anti-inflammatory activity of thrombomodulin results from its ability to block the highly pro-inflammatory activity of thrombin
• Thrombomodulin prevents chemotaxis and binding of granulocytes to activated endothelium and inhibits activation of eosinophils and mast cells thereby reducing inflammation
• Mutations in the CD141 gene result in thromboembolic disease, also known as inherited thrombophilia
• Although expressed across many tissues and cell types, its highest expression has been reported on the luminal surface of vascular endothelial cell
• In the immune system the highest expression can be observed on myeloid cells, including dendritic cells, macrophages and blood monocytes
• In humans, CD141 is commonly used as a marker of cross-presenting dendritic cells in both lymphoid and non-lymphoid tissues
• Retinoic acid has been shown to upregulate CD141 expression on human monocyte-derived dendritic cells and primary human dendritic cells
• Thrombomodulin (TM) is also known as Fetomodulin (FM), endothelial anticoagulant protein, or glycoprotein P112
• Thrombomodulin contains six repeated domains homologous with epidermal growth factor (EGF) and an amino terminal domain homologous to lectin-like protein
• Through its accelerated activation of protein C, synthesis of TM is one of several mechanisms important in maintaining thrombo-resistance and thus reducing clot formation on the surface of the endothelial cells
• Immunohistochemical staining of formalin-fixed tissue for TM has been used for the study of a variety of vascular tumors, meningiomas and choriocarcinomas.